Glycobiology Disease Model Development Service

From Complexity to Clarity: Glycobiology Disease Model Development Service

At CD BioGlyco, our glycobiology disease model development services cover multiple aspects and are designed to meet the needs of different clients in developing glycobiology disease models.

Techniques for in vivo glycobiology disease model development focus on constructing and simulating glycobiology-related disease states in vivo. We use advanced gene editing technologies (such as CRISPR-Cas9), transgenic animal models, and disease-induced models to create animal models with specific glycosylation changes.

• Gene Editing-based In Vivo Glycobiology Disease Model Development Service
• Transgenic-based In Vivo Glycobiology Disease Model Development Service
• Embryo Implantation and Cultivation-based In Vivo Glycobiology Disease Model Development Service
• Selective Breeding-based In Vivo Glycobiology Disease Model Development Service
• Gene Expression-based In Vivo Glycobiology Disease Model Development Service

Glycobiology disease model construction services are one of our core services. We construct cell lines, tissues, or animal models with specific glycosylation modifications or changes in glycan chain structure based on client needs and experimental design. These models are pathological features of known diseases or models that simulate specific biological processes or pathways. We use a variety of technical means, such as cell culture, tissue engineering, and gene editing to ensure the quality and accuracy of the model.

• Autoimmunity and Inflammation Model Construction Service
• Gastrointestinal Disease Model Construction Service
• Cardiovascular Model Construction Service
• Kidney Disease Model Construction Service
• Fibrosis Disease Model Construction Service
• Other Disease Model Construction Service

Customized in vivo glycobiology disease model services are designed to meet individual needs for specific disease models. We work closely with our clients to tailor animal models with specific glycosylation modifications or phenotypes based on their research goals and experimental design. These models simulate specific stages, subtypes, or genetic backgrounds of a disease to more accurately reflect the biology and complexity of the disease.

• Embryonic Stem Cell-based Mice Gene Targeting Services
• CRISPR-Pro-based Services
• Mice or Rat Transgenic Services

In vivo glycobiology disease model screening service mainly targets the screening and evaluation of already constructed animal models. We use a variety of physiological, pathological, and biochemical indicators to test and validate the model comprehensively. These indicators include glycosylation modification levels, protein expression profiles, cell functions, etc. Through screening services, we help clients quickly find models that meet their research needs and evaluate the stability and reliability of the models.

• Vertebrate Model-based In Vivo Screening Service
• Invertebrate Model-based In Vivo Screening Service
• Other Special Model-based In Vivo Screening Service

In vitro glycobiology disease model screening service focuses on model screening at the cellular level. We use cell culture technology and glycobiology analysis methods to detect and evaluate glycosylation modification levels in cell lines or cell models provided by clients. These models can be cell lines based on specific disease types, or cell models genetically edited or induced to differentiate. Through in vitro screening services, we help clients quickly understand the changes in glycosylation in cell models and evaluate the impact of these changes on cell function.

• HeLa Cells-based In Vitro Screening Service
• 3T3-L1 Cells-based In Vitro Screening Service
• Muscle Cells-based In Vitro Screening Service
• Hepatocyte-based In Vitro Screening Service
• Insulin Target Cells-based In Vitro Screening Service
• Intestinal Cells-based In Vitro Screening Service
• THP-1 Monocyte-based In Vitro Screening Service
• Vero Cells-based In Vitro Screening Service

In addition, our glycobiology disease model development services encompass several technologies and processes highly specialized in constructing accurate and reliable models of diseases related to glycobiology.

• Glycomic analysis

We perform glycomic analysis, an omics-scale study of all glycans within an organism, cell, or tissue. This approach is critical for identifying and quantifying glycan changes associated with disease states (disease biomarkers), as glycan abundance and diversity are often correlated with the presence and progression of disease.

• Mass spectrometry analysis: We use mass spectrometry technology (such as LC-MS/MS) to accurately identify and quantify glycan chains in cells or tissues to understand the structure and composition of glycan chains.
• Glycochip technology: We use glycochips to high-throughput screen the interaction between glycans and proteins, antibodies, or other biomolecules to discover potential glycan-binding proteins or glycosylation sites.
• Lectin arrays: We use lectins to specific glycan structures to detect glycosylation patterns in cells or tissues.
• Capillary electrophoresis: We use this technology to analyze glycan mixtures in complex samples to achieve the separation and identification of glycan chains.

• Glycoproteomics analysis

We perform glycoproteomics analyses, a specialized subset of proteomics that focuses on proteins modified by the addition of glycans. Here, we utilize multiple techniques as primary tools for identifying, quantifying, and studying the function of these glycoproteins.

• Glycoprotein isolation and enrichment: We use affinity techniques (such as lectin affinity chromatography) or chemical methods (such as boronic acid affinity chromatography) to isolate and enrich glycoproteins from complex biological samples.
• Glycoprotein identification: We combine mass spectrometry and proteomics technologies to identify and quantitatively analyze glycoproteins to reveal the role of glycosylation modifications in protein function.
• Glycosylation site analysis: We use enzymatic hydrolysis and mass spectrometry technology to accurately locate glycosylation sites on glycoproteins and understand the impact of glycosylation modifications on protein structure and function.

• Disease model development

The cornerstone of our services is the development and validation of disease models. We use innovative techniques to build robust and reproducible disease models that mimic human pathology as closely as possible. These models provide the critical platform necessary to explore disease mechanisms, identify potential therapeutic targets, and test drug candidates.

• Cell models: We use gene editing technology (such as CRISPR-Cas9) to construct cell lines with specific glycosylation modification defects or changes to simulate the glycosylation characteristics of the disease.
• Tissue models: We use three-dimensional culture, organ-on-a-chip, and other technologies to construct tissue models with complex tissue structure and glycosylation characteristics.
• Animal models: We use gene knockout, transgenic, and other technologies to construct animal models that simulate human diseases to study the role of glycosylation in the occurrence and development of diseases.

• Disease model validation

We rigorously validate these disease models after development. This process is designed to ensure that our models accurately represent human disease states. This is essentially mandatory to ensure the predictive validity of our models before further application in a wide range of research areas and drug development.

• Biomarker validation: We validate its potential as a disease biomarker by detecting specific glycosylation modifications or changes in glycan chain structure in disease models.
• Cell function verification: We use cell models to study the impact of glycosylation modifications on biological processes such as cell proliferation, migration, and apoptosis, and to verify the mechanism of glycosylation in diseases.
• Disease phenotype verification: We observe the phenotypic characteristics of the disease in animal models, such as pathological changes, physiological indicators, etc., to verify the association between glycosylation modifications and disease phenotypes.
• Verification of molecular mechanisms: We use molecular biology and cell biology techniques to deeply explore the molecular mechanisms of abnormal glycosylation in the occurrence and development of diseases.

Our technologies are not limited to the list mentioned above. We continually evolve and adapt to the latest technologies in order to provide our clients with the most precise and relevant disease models.

Publication Data

Advantages of Us

• Professionalism and cutting-edge technology: Our company has a profound professional background and cutting-edge technical strength in the field of glycobiology. Our research team consists of experienced glycobiologists and model developers, ensuring that the disease models we develop are highly accurate and reliable.
• Customized services: Our glycobiology disease model development service provides highly customized services. Whether it is targeting a specific disease type, a specific cell type, or a specific glycosylation modification, we customize the design according to the specific needs of our clients to ensure that the model can best meet the research purpose.
• Comprehensive technical support: We provide clients with comprehensive technical support. Our professional team provides technical guidance, data analysis, and interpretation assistance during the model development process to ensure that clients make full use of the model to carry out in-depth research work.

Applications

• Research on disease mechanisms: Researchers develop biological models that simulate the pathological states of specific diseases through the glycobiology disease model development service. These models help reveal the biological mechanisms of diseases and provide new perspectives for disease understanding, prevention, and control.
• Identifying the role of glycans in cell-cell interactions: Glycobiology can be used to determine how different glycan molecules influence intercellular communication and recognition.
• Drug screening platform development: Glycobiological disease models can be used to establish a high-throughput drug screening platform. This platform can be used to evaluate the interaction of drug candidates with disease-relevant glycan molecules to screen for compounds with potential biological activity.

At CD BioGlyco, our glycobiology disease model development service is committed to using advanced glycobiology technologies and methods to build and validate high-quality disease models for clients. We focus on simulating the role of abnormal glycosylation in diseases and helping clients deeply understand the relationship between glycosylation modifications and the occurrence and development of diseases. Please feel free to contact us if you are interested in our glycobiology disease model development service.